(PCVX) Vaxcyte - Ratings and Ratios
Pneumococcal, Streptococcus, Periodontitis, Shigellosis
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 48.4% |
| Value at Risk 5%th | 75.0% |
| Relative Tail Risk | -5.83% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.50 |
| Alpha | -62.70 |
| CAGR/Max DD | 0.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.404 |
| Beta | 0.848 |
| Beta Downside | 0.791 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.22% |
| Mean DD | 24.97% |
| Median DD | 12.46% |
Description: PCVX Vaxcyte November 05, 2025
Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotech focused on next-generation conjugate and protein vaccines against bacterial infections. Its flagship program, VAX-24, is a 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) aimed at preventing invasive pneumococcal disease (IPD) in infants. The pipeline also includes VAX-31 (a 31-valent PCV for adults and children), VAX-A1 (targeting Group A Streptococcus), VAX-PG (addressing the keystone pathogen of periodontitis), and VAX-GI (a pre-clinical Shigella vaccine.
Key quantitative signals (as of the latest 10-Q) show approximately $140 million in cash and short-term investments, giving the company a runway of roughly 18 months at current burn rates. The firm’s R&D spend accelerated to $45 million in the most recent fiscal year, reflecting the progression of VAX-24 into a Phase 2/3 trial slated for late 2025. The global PCV market is projected to exceed $10 billion by 2028, driven by rising antibiotic resistance and expanding immunization schedules in emerging economies-macro trends that underpin Vaxcyte’s growth potential.
Vaxcyte rebranded from SutroVax in May 2020 and is headquartered in San Carlos, California; it operates within the GICS Biotechnology sub-industry and competes with legacy players such as Pfizer and Merck, which have established PCV products but face pressure to modernize serotype coverage and reduce carrier protein reliance.
For a deeper, data-driven valuation of PCVX, the ValueRay platform offers a granular financial model worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.19 (>2.0%) and ΔFCFTA -1.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.17 (>3.0%) and CFO -542.1m > Net Income -657.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (136.2m) change vs 12m ago 10.11% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.41%; Δ -0.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -15.58 (EBITDA TTM -599.8m / Interest Expense TTM 39.6m) >= 6 (WARN >= 3) |
Altman Z'' -7.14
| (A) 0.49 = (Total Current Assets 1.77b - Total Current Liabilities 200.0m) / Total Assets 3.17b |
| (B) -0.60 = Retained Earnings (Balance) -1.91b / Total Assets 3.17b |
| (C) -0.18 = EBIT TTM -617.6m / Avg Total Assets 3.37b |
| (D) -6.84 = Book Value of Equity -1.91b / Total Liabilities 278.7m |
| Total Rating: -7.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.98
| 1. Piotroski 0.0pt |
| 2. FCF Yield -12.78% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.03 |
| 5. Debt/Ebitda 0.33 |
| 6. ROIC - WACC (= -24.80)% |
| 7. RoE -21.08% |
| 8. Rev. Trend 2.80% |
| 9. EPS Trend -62.86% |
What is the price of PCVX shares?
Over the past week, the price has changed by -3.93%, over one month by +11.37%, over three months by +48.60% and over the past year by -47.22%.
Is PCVX a buy, sell or hold?
- Strong Buy: 9
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PCVX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 92 | 92.9% |
| Analysts Target Price | 92 | 92.9% |
| ValueRay Target Price | 46.4 | -2.7% |
PCVX Fundamental Data Overview November 25, 2025
P/B = 2.1621
Beta = 1.289
Revenue TTM = 0.0 USD
EBIT TTM = -617.6m USD
EBITDA TTM = -599.8m USD
Long Term Debt = 84.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.77m USD (from shortTermDebt, last quarter)
Debt = 84.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -196.6m USD (from netDebt column, last quarter)
Enterprise Value = 4.63b USD (6.25b + Debt 84.4m - CCE 1.71b)
Interest Coverage Ratio = -15.58 (Ebit TTM -617.6m / Interest Expense TTM 39.6m)
FCF Yield = -12.78% (FCF TTM -591.5m / Enterprise Value 4.63b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.99m) / Revenue TTM)
Tobins Q-Ratio = 1.46 (Enterprise Value 4.63b / Total Assets 3.17b)
Interest Expense / Debt = 12.71% (Interest Expense 10.7m / Debt 84.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -487.9m (EBIT -617.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.83 (Total Current Assets 1.77b / Total Current Liabilities 200.0m)
Debt / Equity = 0.03 (Debt 84.4m / totalStockholderEquity, last quarter 2.89b)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -196.6m / EBITDA -599.8m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -196.6m / FCF TTM -591.5m)
Total Stockholder Equity = 3.12b (last 4 quarters mean from totalStockholderEquity)
RoA = -20.72% (Net Income -657.2m / Total Assets 3.17b)
RoE = -21.08% (Net Income TTM -657.2m / Total Stockholder Equity 3.12b)
RoCE = -19.29% (EBIT -617.6m / Capital Employed (Equity 3.12b + L.T.Debt 84.4m))
RoIC = -15.65% (negative operating profit) (NOPAT -487.9m / Invested Capital 3.12b)
WACC = 9.15% (E(6.25b)/V(6.34b) * Re(9.14%) + D(84.4m)/V(6.34b) * Rd(12.71%) * (1-Tc(0.21)))
Discount Rate = 9.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.20%
Fair Price DCF = unknown (Cash Flow -591.5m)
EPS Correlation: -62.86 | EPS CAGR: -30.29% | SUE: -0.97 | # QB: 0
Revenue Correlation: 2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.53 | Chg30d=-0.165 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-6.22 | Chg30d=-0.405 | Revisions Net=-2 | Growth EPS=-17.2% | Growth Revenue=+0.0%
Additional Sources for PCVX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle